Shares of Ipca Labs have delivered exceptional returns, surging 36% over the past year and approaching its 52-week high of ₹1,941.40 touched on July 17, 2026. The stock traded 9% higher at ₹1,882.60 at 09:20 AM, significantly outperforming the 0.37% decline in the BSE Sensex. A combined 810,000 equity shares changed hands in the first five minutes of trade on NSE and BSE, demonstrating strong investor interest. The stock's exceptional performance comes after the company reported healthy Q1FY27 results, with the latest surge occurring in an otherwise subdued market environment.
Nomura has raised its target price to ₹2,060 from ₹1,900, implying around 19% upside from current market price. The brokerage has also raised its FY27 and FY28 earnings estimates after the company reported broad-based growth across businesses and geographies in the June quarter. Nomura values Ipca at 27.5 times September 2028 earnings, resulting in its new target price. The brokerage sees a fair valuation range of 23-29 times forward earnings, supported by the domestic formulations business which contributes 45-50% of earnings. While Nomura has moderated its valuation multiple from 29 times, it said this reflects the roll-forward of its target period rather than a deterioration in its fundamental outlook.
The company has significantly upgraded its FY27 financial guidance following exceptional Q1FY27 results. Ipca Labs upgraded its revenue growth guidance to 14-16% from 12-13% and raised consolidated EBITDA margin guidance to 23% from 22%. For Q1FY27, the company reported revenue up 21% year-on-year at ₹2,788.10 crore and reported earnings before interest, taxes, depreciation, and amortization (EBITDA) rose 50% YoY at ₹637.94 crore. The EBITDA margin was 24%, up 600 basis points YoY, while net profit after tax increased 72% YoY at ₹401.89 crore. The company expects US growth at 15-17% with 7-8 launches by Unichem and Ipca, with management targeting a consolidated EBITDA margin of 25-26% by FY29. Nomura estimates underlying revenue and EBITDA growth at around 19% and more than 45%, respectively.
Among key business segments, the India business grew 13% YoY, while the institutional business in exports doubled YoY to ₹120 crore, though ₹40 crore of this growth represented shipments delayed from March into April. The branded formulations performed well with 16% YoY growth, while generics remained relatively weaker at 8% YoY growth. The Active Pharmaceutical Ingredient (API) business was up 33% in exports and 20% in domestic markets. Exports continued to grow at strong pace for the fourth consecutive quarter, led by a robust show in export generics and an increased institutional business. Branded exports sustained mid-teens YoY growth in Q1FY27, with exports and API sales along with improved operating leverage leading better-than-expected performance for the quarter. Nomura highlighted particularly strong performance from the API and export businesses, noting that the company passed on higher raw material costs to API customers and implemented price increases across its India and international branded generics businesses.
Brokerage firms have responded positively to Ipca Labs' strong performance with upgraded estimates and target prices. Motilal Oswal Financial Services has now joined the positive sentiment, recommending a 'BUY' rating with a target price of ₹2,060, raising earnings estimates by 14%/4% for FY26/FY27 and valuing the stock at 30x 12M forward earnings. JM Financial Institutional Securities estimates revenue/EBITDA/PAT to grow by 13%/20%/24% CAGR over FY26-29E and values the stock at 28x to arrive at a target price of ₹2,118 with a 'BUY' rating. Emkay Global Financial has now joined the positive sentiment, recommending a 'BUY' rating with a target price of ₹1,950, representing an 8.3% increase from their previous target. Prabhudas Lilladher has added to the bullish sentiment, recommending a 'Buy' rating with a target price of ₹2,000, valuing the stock at 30x P/E on FY28E. According to management, the margin could eventually reach 25-26% over the next two years, providing another potential earnings growth lever. Nomura expects EBITDA margin to reach 23% in FY27, rising to 24% in FY28 and 24.8% in FY29.
